• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients.高浓度奈非那韦作为人类免疫缺陷病毒感染患者脂肪代谢障碍的独立危险因素。
Antimicrob Agents Chemother. 2002 Dec;46(12):4009-12. doi: 10.1128/AAC.46.12.4009-4012.2002.
2
Liposuction for protease-inhibitor-associated lipodystrophy.用于蛋白酶抑制剂相关脂肪营养不良的抽脂术。
Lancet. 1999 Apr 10;353(9160):1244. doi: 10.1016/S0140-6736(99)01172-1.
3
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.接受HIV蛋白酶抑制剂治疗的患者出现的外周脂肪营养不良、高脂血症和胰岛素抵抗综合征。
AIDS. 1998 May 7;12(7):F51-8. doi: 10.1097/00002030-199807000-00003.
4
Lipodystrophy: results of a data evaluation of patients receiving nelfinavir-containing combination therapy.脂肪代谢障碍：接受含奈非那韦联合治疗的患者数据评估结果
J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):355-6. doi: 10.1097/00126334-200004010-00012.
5
Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.接受蛋白酶抑制剂治疗的HIV-1感染患者发生脂肪代谢障碍的风险：一项前瞻性队列研究。
Lancet. 2001 Feb 24;357(9256):592-8. doi: 10.1016/S0140-6736(00)04056-3.
6
Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.肌细胞和腹部脂肪分配改变预示着HIV蛋白酶抑制剂相关脂肪代谢障碍中胰岛素作用的紊乱。
Diabetes. 2002 Nov;51(11):3163-9. doi: 10.2337/diabetes.51.11.3163.
7
Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus.强效特异性人类免疫缺陷病毒蛋白酶抑制剂奈非那韦的安全性、药代动力学及抗逆转录病毒活性：一项针对人类免疫缺陷病毒感染患者的I/II期试验结果及长期随访
J Clin Pharmacol. 1998 Aug;38(8):736-43. doi: 10.1002/j.1552-4604.1998.tb04814.x.
8
A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin.一名1型人类免疫缺陷病毒感染患者在开始使用奈非那韦后出现全身性癫痫发作，怀疑是奈非那韦与苯妥英钠相互作用所致。
Intern Med. 1999 Mar;38(3):302-3. doi: 10.2169/internalmedicine.38.302.
9
Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy.对有蛋白酶抑制剂相关脂肪代谢障碍证据的人类免疫缺陷病毒感染患者进行内分泌和代谢评估。
J Clin Endocrinol Metab. 1999 Jun;84(6):1925-31. doi: 10.1210/jcem.84.6.5740.
10
Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.利托那韦、奈非那韦及洛匹那韦/利托那韦在接受过抗逆转录病毒治疗的HIV感染儿童中的长期安全性和有效性
Pediatr Infect Dis J. 2008 May;27(5):431-7. doi: 10.1097/INF.0b013e3181646d5a.

引用本文的文献

1
Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.妊娠对奈非那韦-M8药代动力学的影响：一项针对133名女性的群体研究。
Antimicrob Agents Chemother. 2006 Jun;50(6):2079-86. doi: 10.1128/AAC.01596-05.
2
Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.年龄对奈非那韦和M8药代动力学的影响：一项针对182名儿童的群体研究。
Antimicrob Agents Chemother. 2006 Mar;50(3):910-6. doi: 10.1128/AAC.50.3.910-916.2006.
3
High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.在接受高效抗逆转录病毒治疗并获得持续病毒学应答的HIV感染患者中，茚地那韦和奈非那韦药代动力学的高度变异性。
Clin Pharmacokinet. 2005;44(12):1267-78. doi: 10.2165/00003088-200544120-00005.
4
Nelfinavir: a review of its use in the management of HIV infection.奈非那韦：关于其在HIV感染管理中应用的综述
Drugs. 2005;65(15):2209-44. doi: 10.2165/00003495-200565150-00015.
5
Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects.奈非那韦及其代谢产物M8在人类免疫缺陷病毒（HIV）阳性和HIV-丙型肝炎病毒合并感染受试者中的临床药代动力学。
Antimicrob Agents Chemother. 2005 Feb;49(2):643-9. doi: 10.1128/AAC.49.2.643-649.2005.
6
Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?治疗药物监测：有助于优化对抗逆转录病毒药物的反应？
Drugs. 2003;63(8):741-53. doi: 10.2165/00003495-200363080-00002.

本文引用的文献

1
Estimation of body fat from skinfold thickness.根据皮褶厚度估算体脂。
Comput Methods Programs Biomed. 2001 Jun;65(3):201-6. doi: 10.1016/s0169-2607(00)00127-9.
2
Inhibition of adipocyte differentiation by HIV protease inhibitors.HIV蛋白酶抑制剂对脂肪细胞分化的抑制作用。
J Clin Endocrinol Metab. 1999 Nov;84(11):4274-7. doi: 10.1210/jcem.84.11.6234.
3
Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations.根据临床评分定义的接受高效抗逆转录病毒治疗的HIV感染男性的脂肪营养不良：血脂异常与类固醇激素改变之间的相关性。
AIDS. 1999 Nov 12;13(16):2251-60. doi: 10.1097/00002030-199911120-00007.
4
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.人类免疫缺陷病毒1型蛋白酶抑制剂相关脂肪代谢障碍、高脂血症和糖尿病的诊断、预测及自然病程：一项队列研究
Lancet. 1999 Jun 19;353(9170):2093-9. doi: 10.1016/S0140-6736(98)08468-2.
5
Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years.通过总体密度评估身体脂肪及其从皮褶厚度进行的估算：对481名年龄在16至72岁之间的男性和女性的测量。
Br J Nutr. 1974 Jul;32(1):77-97. doi: 10.1079/bjn19740060.
6
The metabolic effects, and the composition of the tissue lost, in weight reduction by obese patients on treatment with fenfluramine.氟苯丙胺治疗肥胖患者减重过程中的代谢效应及丢失组织的成分
Br J Pharmacol. 1973 Sep;49(1):115-20. doi: 10.1111/j.1476-5381.1973.tb08273.x.

高浓度奈非那韦作为人类免疫缺陷病毒感染患者脂肪代谢障碍的独立危险因素。

High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients.

作者信息

Tréluyer Jean-Marc, Morini Jean-Pierre, Dimet Jérome, Gorin Isabelle, Rey Elisabeth, Deleuze Jean, Ceccaldi Pierre-François, Escande Jean-Paul, Pons Gérard, Dupin Nicolas

机构信息

Pharmacologie Périnatale et Pédiatrique, Groupe Hospitalier Cochin-Saint Vincent de Paul (AP-HP), Université René Descartes, 75674 Paris Cedex 14, France.

出版信息

Antimicrob Agents Chemother. 2002 Dec;46(12):4009-12. doi: 10.1128/AAC.46.12.4009-4012.2002.

DOI:10.1128/AAC.46.12.4009-4012.2002
PMID:12435713
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC132744/
Abstract

To assess the relationship between antiretroviral drug exposure and lipodystrophy, 69 human immunodeficiency virus type 1-infected patients receiving nelfinavir were investigated cross-sectionally. Lipodystrophy was defined by patients' self-report. Nelfinavir trough concentrations in plasma were significantly related to overall lipodystrophy and peripheral fat wasting scores and appeared to be an independent risk factor for lipodystrophy

摘要

为评估抗逆转录病毒药物暴露与脂肪代谢障碍之间的关系，对69例接受奈非那韦治疗的1型人类免疫缺陷病毒感染患者进行了横断面研究。脂肪代谢障碍由患者自我报告定义。血浆中奈非那韦谷浓度与总体脂肪代谢障碍及外周脂肪消耗评分显著相关，似乎是脂肪代谢障碍的独立危险因素。